Back Back
Cell No. : Cell Name
RCB2351 : OGU1  update : 2022/01/20
CommentHuman cell line derived from primary effusion lymphoma (PEL). Application consideration
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Kawauchi, Kiyotaka
Originator Kawauchi, Kiyotaka
Year of deposit 2006
Animal human < Mammals
Genus Homo
Species sapiens
Gender Male
Age at sampling 76 years
Tissue ascites
Disease name primary effusion lymphoma
Classification cancer
Year of origin 2000
Lifespan infinite
Morphology lymphocyte-like
Cellosaurus(Expasy) CVCL_4664
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives RPMI1640 + 10% FBS
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) LT 400
Virus (HTLV-1) (-)
Isozyme LD, NP
STR(human) OK
deposit info
lot info
Reference information Reference 2
User's Publication 1

To topTop
7409  Kawauchi K, Ogasawara T, Aiba M, Fujibayashi M, Sanaka T, Sakura H, Shibuya M.  Establishment and characterization of a novel VEGF-producing HHV-8-unrelated PEL-like lymphoma cell line, OGU1.  Eur. J. Haematol.  2015  96:144-51  PubMed ID: 25846106   DOI: 10.1111/ejh.12559
5181  Ogasawara T, Yasuyama M, Kawauchi K.  Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders.  Int J Hematol  2003  77(4):364-70  PubMed ID: 12774925  

To topTop
User's Publication
20882  Ogasawara F, Higuchi T, Nishimori T, Hashida Y, Kojima K, Daibata M.  Targeting VEGF with bevacizumab inhibits malignant effusion formation of primary human herpesvirus 8-unrelated effusion large B-cell lymphoma in vivo.  J Cell Mol Med  2022    PubMed ID: 36209502   DOI: 10.1111/jcmm.17570

Back Back Return Top Page